pteridines and dasatinib

pteridines has been researched along with dasatinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL	1

Other Studies

1 other study(ies) available for pteridines and dasatinib

Article	Year
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. PloS one, 2013, Volume: 8, Issue:10 Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles	2013

Article

Year

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

PloS one, 2013, Volume: 8, Issue:10

Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles

2013